16629-15-5 Usage
Uses
Used in Pharmaceutical Industry:
2-Bromo-5-chlorothiazole is used as a building block for the synthesis of various pharmaceuticals, due to its versatile reactivity and ability to participate in different chemical reactions. This allows for the creation of a wide range of organic compounds with potential therapeutic applications.
Used in Agrochemical Industry:
2-Bromo-5-chlorothiazole is used as a key intermediate in the development of agrochemicals, such as pesticides and herbicides. Its unique structure and properties enable the production of effective and targeted agricultural products, contributing to improved crop protection and yield.
Used in Research and Development:
2-Bromo-5-chlorothiazole is used as a valuable tool for researchers and chemists in the development of new drugs and agricultural products. Its unique structure and properties facilitate the exploration of novel chemical reactions and the synthesis of innovative organic compounds with potential applications in various industries.
Check Digit Verification of cas no
The CAS Registry Mumber 16629-15-5 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,6,6,2 and 9 respectively; the second part has 2 digits, 1 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 16629-15:
(7*1)+(6*6)+(5*6)+(4*2)+(3*9)+(2*1)+(1*5)=115
115 % 10 = 5
So 16629-15-5 is a valid CAS Registry Number.
InChI:InChI=1/C3HBrClNS/c4-3-6-1-2(5)7-3/h1H
16629-15-5Relevant academic research and scientific papers
PYRROLONE MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS
-
Page/Page column 96, (2010/04/28)
The present application provides compounds, including all stereoisomers, solvates, prodrugs and pharmaceutically acceptable forms thereof according to Formula I wherein R1, Formula Ia, R4, R5, Formula Ib, R3, R3a, W, D, R2a, R2b and R2c are defined herein. Additionally, the present application provides pharmaceutical compositions containing at least one compound according to Formula I and optionally at least one additional therapeutic agent. Finally, the present application provides methods for treating a patient suffering from an MCHR-1 modulated disease or disorder such as, for example, obesity, diabetes, depression, anxiety or intestinal inflammation, by administration of a therapeutically effective dose of a compound according to Formula I.
